Radiopharm Theranostics announced that it has entered a collaboration agreement with Lantheus for the mutually beneficial development of NM-01, a nanobody made using genetically engineered camelid derived single domain antibodies, that can be labelled with radioisotopes to potentially diagnose and treat multiple tumor types. In a separate, concurrent agreement, Radiopharm acquired from NanoMab the imaging rights of NM-01 for the strategic Chinese market and worldwide IP rights for any therapeutic use (previously a Licensing right). Radiopharm will shortly initiate a Phase 1 therapeutic trial in Australia in patients with PD-L1 + non-small cell lung cancer (NSCLC).

Radiopharm and Lantheus have agreed to cross-reference each other's data to accelerate the development plans for the PD-L1 assets, including the development and regulatory process with USA Food and Drug Administration (FDA) and other key regulatory agencies. Lantheus provides innovative diagnostics, targeted therapeutics and artificial intelligence (AI) solutions that empower clinicians to Find, Fight and Follow disease. Lantheus holds the exclusive imaging rights to NM-01, apart from China, and recently commenced a Phase 2 clinical trial of NM-01 to evaluate PD-L1 expression in NSCLC patients.

Pursuant to the collaboration agreement, Lantheus will provide the diagnostic product candidate of NM-01 to Radiopharm for use in its therapeutic clinical trials. NM-01 will be used to assess PD-L1 expression during patient selection. In addition, under the agreement, Radiopharm and Lantheus have the option to expand their collaboration to additional assets and potential licensing opportunities in Radiopharm's pipeline.